摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,6-二氨基-1,2-二氢-2,2-二甲基-1-(4'-甲基苯基)-1,3,5-三嗪 | 65972-48-7

中文名称
4,6-二氨基-1,2-二氢-2,2-二甲基-1-(4'-甲基苯基)-1,3,5-三嗪
中文别名
——
英文名称
4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(4'-methylphenyl)-1,3,5-triazine
英文别名
6,6-dimethyl-1-p-tolyl-1,6-dihydro-[1,3,5]triazine-2,4-diyldiamine; hydrochloride;6,6-Dimethyl-1-p-tolyl-1,6-dihydro-[1,3,5]triazin-2,4-diyldiamin; Hydrochlorid;6,6-Dimethyl-1-(4-methylphenyl)-1,3,5-triazine-2,4-diamine;hydrochloride
4,6-二氨基-1,2-二氢-2,2-二甲基-1-(4'-甲基苯基)-1,3,5-三嗪化学式
CAS
65972-48-7
化学式
C12H17N5*ClH
mdl
——
分子量
267.761
InChiKey
YPMIMCWABMFCKU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.39
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    79.4
  • 氢给体数:
    3
  • 氢受体数:
    2

SDS

SDS:556ae36667f27cec5129e81e6abb1f7b
查看

反应信息

  • 作为反应物:
    描述:
    4,6-二氨基-1,2-二氢-2,2-二甲基-1-(4'-甲基苯基)-1,3,5-三嗪 在 sodium hydroxide 作用下, 以 乙醇 为溶剂, 反应 1.0h, 以1.39 g的产率得到6,6-Dimethyl-N2-p-tolyl-1,6-dihydro-[1,3,5]triazine-2,4-diamine
    参考文献:
    名称:
    2,4-二氨基-1,3,5-三嗪衍生物作为神经元电压门控钠通道阻滞剂的合成及体外评价
    摘要:
    神经元钠通道阻滞剂会干扰离子通量,并已用于治疗神经性疼痛,癫痫和脑缺血性疾病。在目前的研究中,合成了四组2,4-二氨基-1,3,5-三嗪衍生物,并研究了它们的神经元钠通道结合活性。在四组三嗪中,发现5-Aryl-1,3,5-triazaspiro [5.5] undeca-1,3-diene-2,4-diamines(4a - 4j)具有最佳的神经元钠结合活性。衍生物4a – 4j用IC 50阻断了钠通道值范围为4.0至14.7μM。这项研究的结果表明,2,4-二氨基-1,3,5-三嗪的类似物可以用作发现神经元钠通道阻滞剂以治疗中枢神经系统相关疾病的先导。
    DOI:
    10.1016/j.bmcl.2009.08.052
  • 作为产物:
    参考文献:
    名称:
    2,4-二氨基-1,3,5-三嗪衍生物作为神经元电压门控钠通道阻滞剂的合成及体外评价
    摘要:
    神经元钠通道阻滞剂会干扰离子通量,并已用于治疗神经性疼痛,癫痫和脑缺血性疾病。在目前的研究中,合成了四组2,4-二氨基-1,3,5-三嗪衍生物,并研究了它们的神经元钠通道结合活性。在四组三嗪中,发现5-Aryl-1,3,5-triazaspiro [5.5] undeca-1,3-diene-2,4-diamines(4a - 4j)具有最佳的神经元钠结合活性。衍生物4a – 4j用IC 50阻断了钠通道值范围为4.0至14.7μM。这项研究的结果表明,2,4-二氨基-1,3,5-三嗪的类似物可以用作发现神经元钠通道阻滞剂以治疗中枢神经系统相关疾病的先导。
    DOI:
    10.1016/j.bmcl.2009.08.052
点击查看最新优质反应信息

文献信息

  • Development of a Lead Inhibitor for the A16V+S108T Mutant of Dihydrofolate Reductase from the Cycloguanil-Resistant Strain (T9/94) of <i>Plasmodium falciparum</i><sup>†</sup>
    作者:Yongyuth Yuthavong、Tirayut Vilaivan、Netnapa Chareonsethakul、Sumalee Kamchonwongpaisan、Worachart Sirawaraporn、Rachel Quarrell、Gordon Lowe
    DOI:10.1021/jm0009181
    日期:2000.7.1
    The Ala16Val+Ser108Thr (A16V+S108T) mutant of the Plasmodium falciparum dihydrofolate reductase (DHFR) is a key mutant responsible for cycloguanil-resistant malaria due to steric interaction between Val-16 and one of the C-2 methyl groups of cycloguanil. 4,6-Diamino-1,2-dihydrotriazines have been prepared, in which both methyl groups of cycloguanil are replaced by H or by H and an alkyl or phenyl group, and their inhibition constants against wild-type and mutant DHFR determined. The S108T mutation is considered to decrease cycloguanil binding further through the effect on the orientation of the p-chlorophenyl group. By moving the p-chloro-substituent to the m-position in the chlorophenyl group, the activity against the A16V+S108T mutant enzyme is improved, and this effect is reinforced by the p-chloro substituent in the 3,4-dichlorophenyl group. A lead compound has been found with inhibitory activity similar to that of cycloguanil against the wild-type DHFR and about 120-fold more effective than cycloguanil against the A16V+S108T mutant enzyme. The activity of this compound against P. falciparum clone (T9/94 RC17) which harbors the A16V+S108T DHFR is about 85-fold greater than cycloguanil.
  • Synthesis and in vitro evaluation of 2,4-diamino-1,3,5-triazine derivatives as neuronal voltage-gated sodium channel blockers
    作者:Xiang Ma、Thong-Yuen Poon、Peter Tsun Hon Wong、Wai-Keung Chui
    DOI:10.1016/j.bmcl.2009.08.052
    日期:2009.10
    the best neuronal sodium binding activity among the four groups of triazines evaluated. Derivatives 4a–4j blocked the sodium channels with IC50 values ranged from 4.0 to 14.7 μM. The result from this study showed that analogues of 2,4-diamino-1,3,5-triazines could be used as leads for the discovery of neuronal sodium channels blockers for managing central nervous system related disorders.
    神经元钠通道阻滞剂会干扰离子通量,并已用于治疗神经性疼痛,癫痫和脑缺血性疾病。在目前的研究中,合成了四组2,4-二氨基-1,3,5-三嗪衍生物,并研究了它们的神经元钠通道结合活性。在四组三嗪中,发现5-Aryl-1,3,5-triazaspiro [5.5] undeca-1,3-diene-2,4-diamines(4a - 4j)具有最佳的神经元钠结合活性。衍生物4a – 4j用IC 50阻断了钠通道值范围为4.0至14.7μM。这项研究的结果表明,2,4-二氨基-1,3,5-三嗪的类似物可以用作发现神经元钠通道阻滞剂以治疗中枢神经系统相关疾病的先导。
查看更多